Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kybella Approval Shows How To Work With FDA On Clinical Outcome Assessments

Executive Summary

Kythera met FDA's strict evidentiary requirements for clinician- and patient-reported outcomes assessments through close and frequent interactions with the agency and by addressing regulatory concerns about the instruments' design, validation and use in Phase III trials for the submental fat treatment.

You may also be interested in...



Allergan Adds Accretive Aesthetics Assets In $2.9bn LifeCell Acquisition

Allergan will pay $2.9bn in cash for LifeCell, a division of Acelity, adding its first regenerative medicine portfolio and marking its first commercial-stage deal in more than a year. The company hopes to exploit the surgical products for aesthetic uses beyond breast reconstruction.

Behind The Approval Letter: Drug Review Profiles

A listing of the Drug Review Profile series articles published in the Pink Sheet.

Chin Fat Not A 'Serious Condition' Worthy Of Priority Review, FDA Says

Deoxycholic acid offers safe and effective alternative to 'unapproved and unregulated' pharmacy compounded products, Kythera asserted in unsuccessful bid for shorter review.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel